Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lia Gore

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALLRegina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Blood Advances|April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Leukemia|September 11, 2024
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group studySusan R Rheingold, Deepa Bhojwani, Lingyun Ji, et al.
The New England Journal of Medicine|December 9, 2024
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenSumit Gupta, Rachel E Rau, John A Kairalla, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Carl Allen, Jason Fangusaro, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancerAndrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew D J Pearson, Sara Federico, Susanne A Gatz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot StudyMichael J Burke, Rumen Kostadinov, Richard Sposto, et al.
Cancer Discovery|February 10, 2021
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP ConsortiumYana Pikman, Sarah K Tasian, Maria Luisa Sulis, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALLRegina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Blood Advances|April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Leukemia|September 11, 2024
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group studySusan R Rheingold, Deepa Bhojwani, Lingyun Ji, et al.
The New England Journal of Medicine|December 9, 2024
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenSumit Gupta, Rachel E Rau, John A Kairalla, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Carl Allen, Jason Fangusaro, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancerAndrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew D J Pearson, Sara Federico, Susanne A Gatz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot StudyMichael J Burke, Rumen Kostadinov, Richard Sposto, et al.
Cancer Discovery|February 10, 2021
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP ConsortiumYana Pikman, Sarah K Tasian, Maria Luisa Sulis, et al.
Pageof 12